Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis by Hendrik Eggers, Philipp Ivanyi, Mareike Hornig, Viktor Grünwald

Get full text

Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches by Philip Posdzich, Christopher Darr, Thomas Hilser, Milan Wahl, Ken Herrmann, Boris Hadaschik, Viktor Grünwald

Get full text

The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape by Christian Doehn, Martin Bögemann, Viktor Grünwald, Manfred Welslau, Jens Bedke, Martin Schostak, Thomas Wolf, Rainer Ehneß, Elisa Degenkolbe, Stefanie Witecy, Peter J. Goebell

Get full text

Synovial sarcoma of the kidney in a young patient with a review of the literature by Mahmoud Abbas, Maximilian E. Dämmrich, Peter Braubach, Andre Meinardus, Mario W. Kramer, Axel S. Merseburger, Thomas R.W. Herrmann, Viktor Grünwald, Hans-Heinrich Kreipe

Get full text

DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies. by Inga Peters, Natalia Dubrowinskaja, Mahmoud Abbas, Christoph Seidel, Michael Kogosov, Ralph Scherer, Kai Gebauer, Axel S Merseburger, Markus A Kuczyk, Viktor Grünwald, Jürgen Serth

Get full text

New Prognostic Score (Essen Score) to Predict Postoperative Morbidity after Resection of Lung Metastases by Konstantinos Grapatsas, Fabian Dörr, Hruy Menghesha, Martin Schuler, Viktor Grünwald, Sebastian Bauer, Hartmut H. -J. Schmidt, Stephan Lang, Rainer Kimmig, Stefan Kasper, Natalie Baldes, Servet Bölükbas

Get full text

Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient^® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarc... by Daniel Pink, Dimosthenis Andreou, Sebastian Bauer, Thomas Brodowicz, Bernd Kasper, Peter Reichardt, Stephan Richter, Lars H. Lindner, Joanna Szkandera, Viktor Grünwald, Maxim Kebenko, Marietta Kirchner, Peter Hohenberger

Get full text

High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy by Ulrich Krafft, Csilla Olah, Henning Reis, Claudia Kesch, Christopher Darr, Viktor Grünwald, Stephan Tschirdewahn, Boris Hadaschik, Orsolya Horvath, Istvan Kenessey, Peter Nyirady, Melinda Varadi, Orsolya Modos, Anita Csizmarik, Tibor Szarvas

Get full text

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study by Melinda Váradi, Orsolya Horváth, Orsolya Módos, Tamás Fazekas, Camilla M. Grunewald, Günter Niegisch, Ulrich Krafft, Viktor Grünwald, Boris Hadaschik, Csilla Olah, Anikó Maráz, Andrea Furka, Miklós Szűcs, Péter Nyirády, Tibor Szarvas

Get full text

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer by Csilla Olah, Henning Reis, Michèle J. Hoffmann, Fabian Mairinger, Saskia Ting, Boris Hadaschik, Ulrich Krafft, Viktor Grünwald, Peter Nyirady, Melinda Varadi, Balázs Győrffy, Andras Kiss, Eszter Szekely, Gottfrid Sjödahl, Tibor Szarvas

Get full text

1294 External validation of machine learning models to predict efficacy and toxicity of immune checkpoint inhibitors using real-world pan cancer cohorts by Jens Siveke, Alexander Roesch, Viktor Grünwald, Zoltan Kiss, Jan Wolber, Martin Schuler, Julius Keyl, Levente Lippenszky, Pablo Napan-Molina, Eszter Csernai, Travis Osterman, Balazs Laczi, Alexander Brehmer, Moon Kim, Moritz Meyer, Stefan Kasper, Jens Kleesiek

High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma by Ádám Széles, Petra Terézia Kovács, Anita Csizmarik, Melinda Váradi, Péter Riesz, Tamás Fazekas, Szilárd Váncsa, Péter Hegyi, Csilla Oláh, Stephan Tschirdewahn, Christopher Darr, Ulrich Krafft, Viktor Grünwald, Boris Hadaschik, Orsolya Horváth, Péter Nyirády, Tibor Szarvas

Get full text

Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study) by Philip Zeuschner, Sebastian Hölters, Michael Stöckle, Barbara Seliger, Anja Mueller, Hagen S. Bachmann, Viktor Grünwald, Daniel C. Christoph, Arnulf Stenzl, Marc-Oliver Grimm, Fabian Brüning, Peter J. Goebell, Marinela Augustin, Frederik Roos, Johanna Harde, Iris Benz-Rüd, Michael Staehler, Kerstin Junker

Get full text

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial by Viktor Grünwald, Daniel Pink, Gerlinde Egerer, Enrico Schalk, Marinela Augustin, Christoph K. W. Deinzer, Viola Kob, Dietmar Reichert, Maxim Kebenko, Stephan Brandl, Dennis Hahn, Lars H. Lindner, Mathias Hoiczyk, Uta Ringsdorf, Lars C. Hanker, Dirk Hempel, Beatriz De Rivas, Tobias Wismann, Philipp Ivanyi

Get full text

Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. by Paolo Grassi, Ludovic Doucet, Palma Giglione, Viktor Grünwald, Bohuslav Melichar, Luca Galli, Ugo De Giorgi, Roberto Sabbatini, Cinzia Ortega, Matteo Santoni, Aristotelis Bamias, Elena Verzoni, Lisa Derosa, Hana Studentova, Monica Pacifici, Jorgelina Coppa, Vincenzo Mazzaferro, Filippo de Braud, Camillo Porta, Bernard Escudier, Giuseppe Procopio

Get full text

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms by Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri

Get full text

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms by Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri

Get full text

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort by Stefanie Zschäbitz, Nadine Biernath, Thomas Hilser, Alexander Höllein, Friedemann Zengerling, Jozefina Cascucelli, Pia Paffenholz, Daniel Seidl, Christoph Lutz, Katrin Schlack, Dorothea Kingreen, Niklas Klümper, Philipp Ivanyi, Gunhild von Amsberg, Hendrik Heers, Florian Roghmann, Robert L. Tauber, Richard Cathomas, Luisa Hofer, Günter Niegisch, Melanie Klee, Roland Ehrenberg, Andreas Hassler, Boris A. Hadaschik, Viktor Grünwald, Christopher Darr

Get full text